



KLUVAGUT

Kluyveromyces Marxianus Fragilis B0399 10 Million CFU Capsules


KLUVAGUT

Kluyveromyces Marxianus Fragilis B0399 10 Million CFU Capsules

BACKGROUND:

- Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder, characterized by recurrent abdominal pain, cramping, bloating, constipation, and diarrhea, in the absence of detectable structural abnormalities.
- In the Asian population, the prevalence of IBS ranges from 3.7% to 22%, and 70% of IBS sufferers report abdominal pain or discomfort that seriously lowers their quality of life^{1,2}.


PATHOPHYSIOLOGY OF IRRITABLE BOWEL SYNDROME:



Intestinal microbiota and the mucosal immune system can significantly impact human health. In this context, fungi and food-related yeasts are known to influence intestinal inflammation through direct interactions with specialized immune cells.³

NEW GENERATION PROBIOTIC LACTIC YEAST - KLUVAGUT (KLUYVEROMYCES MARXIANUS FRAGILIS B0399)

Kluyveromyces marxianus (formerly *Kluyveromyces fragilis*) is a lactic yeast isolated from different dairy products, mainly kefir.⁴



CLINICAL EVIDENCE:

Clinical results of treatment with the lactic yeast *Kluyveromyces* B0399 for Irritable Bowel Syndrome.¹⁰




NO. OF PATIENTS: 50 Patients

DURATION: 3 Months

DOSE:

- **Starting Dose:** 2 Capsules/Day before breakfast for a month
- **Maintenance Dose:** 1 Capsule/Day before breakfast for two months.

RESULT:



CONCLUSION:

Prolonged administration of *Kluyveromyces marxianus fragilis* B0399 significantly improves the clinical condition and above all it improves the quality of life of the patients.



KLUVAGUT

KLUVAGUT

Kluyveromyces Marxianus Fragilis B0399 10 Million CFU Capsules

DESCRIPTION:

KLUVAGUT contains Kluyveromyces Marxianus Fragilis B0399 10 million CFU and is available as a hard gelatin capsule. It is a lactic yeast that helps in the modulation of the intestinal environment and rebalancing the gut flora.

INDICATION:

Irritable Bowel Syndrome (IBS)

MODE OF ACTION:

Kluyveromyces Marxianus Fragilis B0399 has been demonstrated to exert health-promoting effects through several proposed mechanisms:

- K. marxianus B0399 is highly adhesive to human enterocyte-like Caco-2 cells and modulates the production of 27 immune mediators (cytokines, chemokines, and growth factors) in Caco-2 cells and peripheral blood mononuclear cells (PBMCs).⁴
- K. marxianus B0399 has elevated lactase enzymatic activity (β -galactosidase), It ferments lactose with the production of lactic acid.⁵
- Provides energy and promotes colon epithelial cell growth by stimulating short-chain fatty acetate and propionate production.⁴
- Contributes in the modulation of the intestinal environment, reducing the pH⁴
- It efficiently stimulates development of the good gut flora (e.g. endogenous Bifidobacteria)- even at low dosage.

KEY BENEFITS OF KLUVAGUT OVER COMMONLY USED PROBIOTIC:

Kluyveromyces Marxianus Fragilis B0399,

- Has a high growth rate, high thermostability and high content of mannan content in the cell wall.¹¹
- Has unique biological properties such as: natural & gut friendly, lactose degrading.¹²
- Natural antibiotic resistance and compatibility with antibiotic therapy.⁵
- The natural resource of prebiotics: Beta-glucans & oligosaccharides (GOS, MOS, FOS).¹³
- Maintains its vitality and fermentation capacity.⁴
- Suitable for lactose-intolerant patients.⁵
- Prevents & inhibits the development of pathogen.
- Stimulates the development of the good endogenous flora.
- Effective dosage and concentration.

DOSAGE:

The recommended dose of **KLUVAGUT** is 1-2 capsules per day or as directed by the Physician.

STORAGE:

Store below 25°C. Protected from light and moisture.

PRESENTATION:

KLUVAGUT is available as a strip of 10 Capsules.

References:

1. xue et al. medicine (2017) 96:51
2. The saudi journal of gastroenterology, volume 20
3. Regulatory Immune Response Induced by K. marxianus
4. Probiotic Potential of K. marxianus B0399, Volume 78
5. Trial130.1 SANI TS Mustacchi/kluyveromyces B03999 nelle feci.

6. Applied and Environmental Microbiology p. 956–964
7. MINERVA GASTROENTEROLOGICA E DIETOLOGICA, Vol. 57 – Suppl 1 al N. 2
8. 10.1080/19440049.2017.1290830
9. Journal of Dairy Science Volume 99, Issue 1, January 2016, Pages 120–129
10. TURVAL Laboratories Ltd Italy: Trial 16

11. Effects of Kluyveromyces marxianus on broilers, July 10, 2017
12. Truval Trial number 125,132,138
13. Yeasts and Molds | Kluyveromyces spp. , 2011 Elsevier Ltd

La Renon Healthcare Private Limited

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads, S.G. Highway, Ahmedabad-380015, Gujarat, India.
Phone: + 91-79-6616-8998, 2693-6656 | Fax: +91-79-6616-8998 | E-mail: info@larenon.com | Web: www.larenon.com

©2023 All rights reserved, La Renon Healthcare Private Limited